A recent analysis found a third-generation EGFR-TKI to offer superior efficacy compared with standard EGFR-TKIs in the first-line setting for EGFR-positive advanced NSCLC.

Research in Review

A study of SMARCA/BRG1 expression in patients with non-small cell lung (NSCLC) cancer has found that it is a significant indicator of prognosis and a novel predictive biomarker for increased sensitivity to platinum-based chemotherapy.

Read More

Early results of a head-to-head trial comparing two prominent treatments for patients with EGFR mutation-positive non-small cell lung cancer (NSCLC) could have a significant impact on clinical decision making for this patient population.

Read More

A newly developed “liquid biopsy” assay that detects free-floating DNA from cells in blood plasma may be an effective tool for detecting mutations in patients with non-small cell lung cancer (NSCLC), according to the results from a recent study.

Read More

Subscribe to Non-Small Cell Lung Cancer